Overview

Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial

Status:
Recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
PEGASUS is a prospective multi-centric study designed to prove the feasibility of using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
IFOM, The FIRC Institute of Molecular Oncology
Collaborator:
Guardant Health, Inc.
Treatments:
Capecitabine